Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $457
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $480 to $457.
Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $480 to $457.